专利名称：Survivin-directed cancer vaccine therapy 发明人：Geissler, Simon,Boniforte, Patrizia,Plaschke, Joerg,Weigandt, Markus,Jaekel,
truncated 带where
Stefan,Kellner, Roland,Rysiok,
Thomas,Mueller-Pompalla, Dirk,Hance,
Kenneth
申请号：AU2014365888
申请日：20141216
公开号：AU2014365888A1
公开日：
20160728
专利内容由知识产权出版社提供
摘要：The invention relates to a therapeutically effective truncated survivin and its therapeutic use as vaccine in a liposomal preparation, wherein the survivin fragment is preferably gluconoylated, and said liposomal preparation elicits in-vivo anti-tumor activity. The invention is directed, in more detail, to a cancer vaccine comprising a fragment of human survivin that is specifically effective in conjunction with an lipid adjuvant. The invention relates in more detail to a liposomal vaccine delivery system comprising an active truncated survivin molecule as tumor antigen and a chiral cationic lipid, for example R-DOTAP acting as adjuvant, which is part of the liposome preparation, wherein the liposomal drug delivery system is optimized with regard to its lipid and adjuvant components, physical or physicochemical parameters, and the final therapeutic efficacy of the released truncated survivin molecules. The invention is finally related to a method of increasing CD4
申请人：Merck Patent GmbH
代理人：Griffith Hack
更多信息请下载全文后查看

版权声明：本站内容均来自互联网，仅供演示用，请勿用于商业和其他非法用途。如果侵犯了您的权益请与我们联系QQ:729038198，我们将在24小时内删除。